Cancer immunotherapy has transformed oncology by shifting part of the fight against tumors from conventional chemotherapy and radiation toward the patient’s own immune system. Among the most important advances are immune checkpoint inhibitors, which release molecular brakes that restrain T cells, and engineered or expanded T-cell therapies designed to target malignant cells. Yet these treatments remain ineffective for many patients. Some tumors lack the biological signals needed for T-cell recognition, while others create a hostile microenvironment that suppresses immune activity or evolve rapidly enough to escape attack.

T cells are specialized immune cells capable of identifying abnormal proteins displayed on the surface of cancer cells. After recognizing their targets, they form a close contact zone with the tumor cell, known as an immunological synapse, and release toxic molecules that can trigger the cancer cell to die. This process depends on a series of precisely coordinated interactions between the T cell and the tumor. If any part of that process is weakened—whether because the tumor hides its identifying markers, blocks immune signaling or resists cell death—the immune response may fail even when large numbers of T cells are present.

To search for ways to overcome these barriers, Puig-Saus’ laboratory has developed a drug screening platform capable of testing thousands of chemical compounds. Such platforms allow scientists to observe how individual molecules influence interactions between immune cells and cancer cells. Rather than examining only whether a drug kills tumor cells directly, the UCLA team can investigate whether a compound changes the biological relationship between the tumor and the immune system. This distinction is important because many promising immunotherapy-enhancing drugs may not be effective as standalone cancer treatments.

The screening effort has identified two leading candidates with complementary effects. One compound appears to strengthen the physical and functional interaction between T cells and cancer cells. By improving the formation or stability of the cellular contact needed for immune attack, the drug could help T cells deliver their destructive signals more effectively. This type of intervention may be especially valuable in tumors where immune cells reach the cancer but fail to establish a sufficiently strong or sustained response.

The second candidate acts primarily on tumor cells rather than directly modifying T cells. Preliminary findings suggest that it makes cancer cells more vulnerable to destruction by T cells. In technical terms, the drug may alter pathways controlling tumor-cell survival, stress responses or susceptibility to the molecular machinery released by activated immune cells. The compound could therefore increase the “killability” of cancer cells without requiring researchers to permanently reprogram or intensify the immune cells themselves, potentially offering a different route to improving treatment efficacy.

The new grant will support experiments in preclinical melanoma models to determine whether either compound can boost existing immunotherapies. Researchers will evaluate combinations with immune checkpoint inhibitors and T-cell-based treatments, measuring tumor growth, immune-cell activity, treatment durability and possible toxic effects. They will also study how the compounds work at the molecular level, seeking to identify the cellular pathways responsible for improved immune recognition or tumor destruction. Understanding those mechanisms will be essential for selecting appropriate patients and designing safe clinical trials.

Melanoma provides a particularly important testing ground because it can carry a high number of mutations, creating abnormal proteins that immune cells may recognize. Despite this vulnerability, melanoma can still suppress immune responses and develop resistance after an initial treatment benefit. A drug that restores the effectiveness of T cells or exposes a tumor’s hidden weaknesses could help extend responses in patients who do not benefit from current therapies or whose cancers return after treatment. The researchers will need to establish whether the compounds work broadly across genetically different melanomas or only in tumors with particular biological features.

“If successful, these drugs could significantly improve the effectiveness of current immunotherapies and help more patients benefit from these treatments,” Puig-Saus said. She is an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA. She is also a member of the UCLA Broad Stem Cell Research Center and the UCLA Parker Institute for Cancer Immunotherapy. Because the compounds are being developed as partners for existing treatments rather than replacements for them, the strategy could potentially be adapted to other cancers in which immune evasion and resistance limit therapeutic success.

The project remains at the preclinical stage, and its compounds have not yet been established as safe or effective treatments for people. Many candidates that show promise in laboratory systems ultimately fail because they produce unexpected toxicity, lose activity in complex tumors or cannot be delivered at useful doses. The UCLA team’s upcoming studies will therefore examine both therapeutic benefit and safety while tracing the precise mechanisms involved. If the candidates continue to perform well, they could provide a foundation for future clinical development and offer a new way to make the immune system’s attack on cancer more precise, persistent and effective.

Subject of Research: Cancer immunotherapy enhancement using drug-based strategies for melanoma and potentially other cancers

Article Title: UCLA Team Receives $3.9 Million Grant to Develop Drugs That Could Strengthen Cancer Immunotherapy

Web References: https://www.uclahealth.org/cancer/members/cristina-puig-saus; https://www.uclahealth.org/cancer

Keywords: Immunotherapy, cancer immunology, immune system, immune response, cancer research, cancer, melanoma, skin cancer, T-cell therapy, immune checkpoint inhibitors

Messenger RNA (mRNA) vaccines have undoubtedly transformed public health, especially highlighted by their rapid deployment during the COVID-19 pandemic. However, their variable efficacy among individuals and the need for frequent updates to counter viral mutations have exposed critical vulnerabilities. Manufacturing complexities, stringent cold chain requirements, and unpredictable dosing within lipid nanoparticle delivery vehicles have also underscored the necessity for complementary strategies. The DNA origami-based DoriVac seeks to address these challenges by enabling unparalleled control over vaccine composition at the nanoscale, ensuring precise spatial arrangement of immune-stimulating elements and antigens.

At the heart of DoriVac’s technology lies DNA origami, a technique that engineers DNA to fold into highly defined three-dimensional nanostructures. These square block-shaped constructs serve a dual purpose: one face displays immune-activating adjuvant molecules, while the opposing side presents pathogen-specific antigens. This spatially controlled display is critical; by tuning the nanometer-scale distances between adjuvant molecules, researchers optimize the activation of dendritic cells, the immune system’s sentinel antigen-presenting cells. Enhanced dendritic cell activation cascades into a more vigorous and diverse mobilization of humoral and cellular immunity, including potent B cell antibody production and activation of CD4+ and CD8+ T cell subsets essential for viral clearance and long-term protection.

The Wyss Institute team deployed the DoriVac platform to develop vaccines that incorporate the HR2 peptide, a conserved region found in the spike proteins of diverse viruses such as SARS-CoV-2, HIV, and Ebola. These vaccines elicited compelling immune responses in murine models, significantly surpassing those generated by free antigens and adjuvants administered without the nanostructured framework. Notably, the SARS-CoV-2 HR2-targeting DoriVac induced a broad spectrum of immune cells, encompassing activated dendritic cells, memory T cells proficient in cytotoxic functions, and antibody-secreting plasma cells, all key players in sustained antiviral immunity.

Transitioning from animal studies to human systems, researchers employed an advanced human lymph node-on-a-chip platform to simulate and assess how DoriVac would perform in a human immune context. This microfluidic technology provides a dynamic and controllable environment that closely mimics the physiology of human lymphoid tissue, where initial immune activation occurs. Here, the SARS-CoV-2 HR2 DoriVac vaccine profoundly stimulated dendritic cells to secrete inflammatory cytokines and expanded populations of functional CD4+ and CD8+ T cells. Such results underscore the considerable translational potential of DoriVac vaccines and support their progression toward clinical evaluation.

Perhaps most strikingly, direct comparisons between DoriVac vaccines presenting the full SARS-CoV-2 spike protein and commercially available mRNA vaccines from Moderna and Pfizer/BioNTech revealed that DoriVac could elicit comparable levels of T cell and B cell responses. This parity was observed in preclinical mouse models receiving booster doses—a gold standard in assessing vaccine efficacy. The implications extend beyond immune activation; the structural stability of DoriVac vaccines circumvents the necessity for ultracold storage that hampers mRNA vaccine distribution, particularly in resource-constrained settings. Moreover, the relatively straightforward manufacturing process promises scalability and cost-effectiveness, factors critical for global vaccine accessibility.

The molecular precision of DoriVac offers significant advantages in safety and customization. By programming immune recognition mechanisms at the nanoscale, it minimizes off-target effects commonly associated with lipid nanoparticle-based delivery systems. Additionally, the self-adjuvanted nature of the DNA origami vaccine enhances immune stimulation without requiring separate adjuvant components. Early studies indicate a favorable safety profile, further substantiating the platform’s suitability for diverse clinical applications.

DoriVac’s creation is the culmination of interdisciplinary collaboration integrating expertise from structural DNA nanotechnology, immunology, microengineering, and virology. Led by Professor William Shih and Dr. Yang (Claire) Zeng, the initiative represents a fusion of fundamental science and translational vision. Zeng’s leadership in advancing DoriVac encompassed initial cancer immunotherapy applications, which serendipitously dovetailed with infectious disease needs amidst the ongoing pandemic. The coupling of DNA origami with organ-on-chip technologies, engineered by Dr. Donald Ingber’s team, exemplifies this synergy, producing predictive human immune models conducive to accelerating vaccine development cycles.

As the scientific community anticipates the next generation of vaccines with enhanced efficacy, durability, and accessibility, platforms like DoriVac may form the cornerstone of future pandemic preparedness. Their modularity permits rapid reprogramming to address emerging pathogens, while their robust immune activation profiles enhance both the magnitude and breadth of protective responses. This novel approach not only augments our arsenal against known viral threats but also charts a sophisticated path to anticipate and mitigate future infectious disease challenges.

With promising preclinical data validating the feasibility and superiority of DoriVac, the research consortium is poised to advance toward clinical trials. Commercialization efforts led by DoriNano, co-founded by Dr. Zeng, aim to translate this innovation from laboratory benches to global healthcare systems. Their success could redefine vaccine paradigms, merging the blueprint of life, DNA, with cutting-edge immunoengineering, to deliver vaccines that are smarter, safer, and more widely available.

In sum, DoriVac represents an exciting convergence of nanotechnology and immunotherapy, encapsulating the potential to revolutionize vaccine science. By delivering a potent cocktail of vaccine and adjuvant with nanometer precision, this platform amplifies immune responses beyond current capabilities. Its stability and manufacturability hold promise for equitable distribution worldwide, breaking down barriers imposed by cold chains and supply complexities. As infectious diseases continue to challenge humanity, such innovations may well be our most formidable defense.

Subject of Research: Animals

Article Title: DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases

Web References:

• Wyss Institute Technology: DoriVac Information
• Wyss Institute at Harvard University: https://wyss.harvard.edu

Image Credits: Wyss Institute at Harvard University

Keywords: DNA origami, vaccine development, infectious diseases, immunology, adjuvants, dendritic cells, antigen presentation, humoral immunity, cellular immunity, SARS-CoV-2, mRNA vaccines, nanotechnology

Tuberculosis remains a major public health threat, especially in low- and middle-income countries. Despite significant advances in diagnosis and antibiotic therapy, treatment failure and disease relapse continue to undermine global control efforts. Central to TB’s resilience is the formation of granulomas—organized aggregates of immune cells that sequester the bacteria but also create a niche favoring persistence and latent infection. The inability of conventional therapies to fully penetrate this architectural and biochemical fortress has long frustrated clinicians and researchers, necessitating therapeutic innovations capable of overcoming these biological barriers.

The research team has ingeniously harnessed the power of sono-immunotherapy, an emerging modality that utilizes the mechanical and biological effects of focused ultrasound to enhance immune response. By directing ultrasound waves at granulomas, the therapy modulates the local microenvironment in a way that both disrupts the protective niche for Mtb and amplifies the host immune system’s ability to recognize and eradicate the infected cells. This dual mechanism breaks the stalemate between bacterial persistence and immune containment, signaling a paradigm shift in TB therapy.

Granulomas create a hypoxic, acidic, and immunosuppressive local milieu aimed at limiting bacterial dissemination but paradoxically fostering Mtb’s dormancy and antibiotic tolerance. The researchers meticulously characterized this microenvironment, identifying key features that impair immune cell function and reduce drug bioavailability. Their approach employing ultrasound serves to transiently remodel this microenvironment, improving oxygenation and pH balance while facilitating better penetration of immune cells and therapeutic agents. Such dynamic remodeling is critical to reversing the immunosuppressive status quo within granulomas.

One of the study’s most noteworthy aspects is the targeted immunomodulation. Ultrasound exposure induces mechanical stress and mild hyperthermia, which enhance antigen presentation and increase the expression of co-stimulatory molecules on macrophages and dendritic cells resident in granulomas. This stimulation galvanizes T-cell responses critical for long-term immunity and reduces Mtb’s ability to evade immune detection. The upregulation of immune checkpoint molecules is also modulated, preventing excessive inflammation while maintaining effective bacterial clearance.

Integrating immunotherapy with ultrasound offers advantages over traditional drug regimens. By localizing treatment effects within granulomas, systemic toxicity can be minimized, reducing adverse effects often associated with prolonged antibiotic use. Moreover, the therapy’s non-invasive nature and ability to be finely tuned in real time provide a versatile tool adaptable to patient-specific disease presentations and granuloma heterogeneity. This personalized approach aligns with precision medicine goals and could revolutionize TB treatment paradigms.

The research utilized advanced imaging and molecular profiling techniques to monitor therapeutic effect in vivo. Longitudinal assessments revealed substantial reductions in granuloma size and bacterial load following sono-immunotherapy application. Importantly, treated subjects demonstrated a dramatic decrease in recurrence rates during extended follow-up periods compared to controls receiving standard care. These outcomes underscore the durability and efficacy of targeting granuloma microenvironments as a means of long-term disease control.

Fundamental to the study’s success is the multidisciplinary collaboration bridging microbiology, immunology, biomedical engineering, and clinical medicine. The team developed a sophisticated ultrasound delivery system capable of penetrating deep tissue layers with precision, minimizing off-target effects. Parallel investigations into signaling pathways activated by mechanical stimulation unveiled novel insights into host-pathogen interactions, opening avenues for further therapeutic innovation beyond TB.

The researchers also addressed potential limitations. They emphasized the need for careful calibration of ultrasound parameters to avoid tissue damage and preserve the structural integrity of healthy lung tissue. Strategies for optimizing treatment duration and frequency were explored, balancing maximal immunological benefit against practical considerations such as patient compliance and device accessibility. They proposed integration with existing antibiotic protocols to harness synergistic effects for comprehensive management.

Global implications of this work are far-reaching, especially considering the staggering morbidity and mortality caused by TB worldwide. The technology’s scalability and adaptability render it promising for deployment in resource-limited settings, where TB burden is highest and infrastructure for complex treatments may be scarce. Portable ultrasound devices combined with immunotherapeutic agents represent a feasible and impactful intervention to reduce disease transmission and improve patient outcomes on a population scale.

Furthermore, the principles elucidated herein may extend to other granulomatous diseases characterized by persistent, localized infections or chronic inflammation. The concept of microenvironment-guided sono-immunotherapy opens a new frontier in treating conditions where conventional therapies have failed to achieve durable remission. As such, the study’s impact transcends tuberculosis, positioning it as a beacon for innovation in infectious disease therapeutics.

Looking forward, ongoing clinical trials inspired by this preclinical research are poised to validate safety and efficacy in diverse human populations. The integration of biomarkers to predict responsiveness and monitor therapeutic progress will refine patient selection and treatment personalization. Additionally, exploration of adjunctive agents to potentiate ultrasound-induced immunomodulation may further enhance clinical success.

In summary, the integration of granuloma microenvironment-guided sono-immunotherapy represents a sophisticated, targeted approach to one of humanity’s oldest and most stubborn infectious diseases. By leveraging mechanical forces to convert immunosuppressive niches into active battlegrounds, this technology promises to revolutionize tuberculosis therapy, mitigate recurrence, and pave the way for innovative treatments of other complex infectious conditions. This study epitomizes the power of interdisciplinary research in overcoming longstanding biomedical challenges.

As tuberculosis continues to challenge global health systems, embracing such novel, mechanistically informed therapeutic strategies holds the potential not just to improve individual patient outcomes but to catalyze public health breakthroughs at the global scale. The scientific community and healthcare practitioners alike eagerly anticipate the translation of this promising technology from bench to bedside, heralding a new era in infectious disease control.

Subject of Research: Sono-immunotherapy targeting the granuloma microenvironment to treat and prevent tuberculosis recurrence.

Article Title: Granulomas microenvironment-guided sono-immunotherapy to treat and prevent recurrence of tuberculosis.

Article References:
Wang, W., Li, F., Mo, W. et al. Granulomas microenvironment-guided sono-immunotherapy to treat and prevent recurrence of tuberculosis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69420-1

Image Credits: AI Generated

Hepatocellular carcinoma, which ranks as the third leading cause of cancer-related mortality worldwide, has proven resistant to conventional treatments. The complexity of HCC lies in its ability to evade both innate and adaptive immune responses, leading to poor outcomes. This new research provides a compelling framework for overcoming these challenges by employing CAR-engineered macrophages that target cancer cells expressing the NKG2D ligand, a crucial element in the immune surveillance process.

The essence of this innovative approach lies in the dual function of the CAR-macrophages. Unlike traditional CAR-T therapies that focus solely on T-cells, the study capitalizes on macrophages, a type of innate immune cell known for their phagocytic capabilities and inflammatory responses. Macrophages can provide a robust front-line defense, engaging not only in direct cytotoxicity but also orchestrating the broader immune response, which is vital for long-term protection against tumor recurrence.

Research indicates that the NKG2D receptor, which is expressed on the surface of certain immune cells, including natural killer (NK) cells and CD8+ T-cells, plays a significant role in recognizing and eliminating tumor cells. By engineering macrophages to express CAR specific to the NKG2D ligand, the researchers have created a situation where these immune cells can precisely hone in on cancer cells, initiating a potent immune response that could turn the tide in the fight against HCC.

In vitro studies demonstrate the efficacy of NKG2D-specific CAR-macrophages in triggering a cascade of immune activations. When exposed to HCC cells, these modified macrophages exhibited enhanced phagocytosis and secretion of pro-inflammatory cytokines, which are crucial for amplifying the immune response against the tumor. The findings suggest that by priming the innate immune system, these cells could effectively bridge the gap between innate and adaptive immunity, facilitating a more comprehensive attack on the cancer.

One of the most promising aspects of this research is its focus on achieving durable remission. The team employed a series of animal model experiments to assess the long-term effects of this therapy. The results were impressively consistent, with treated mice demonstrating significant tumor regression and prolonged survival times compared to controls. This durability of response is critical, as many current therapies often lead to temporary remission with the inevitable return of cancer.

Moreover, the study delves into the mechanistic insights of how NKG2D-specific CAR-macrophages interact with the tumor microenvironment. Underneath the surface, HCC cells often manipulate the immune milieu to foster an immune-suppressive environment. By utilizing CAR-macrophages that can actively engage with these cancer cells and potentially disrupt their immunosuppressive tactics, the researchers have opened a new discussion on how we can combat tumor escape mechanisms.

Furthermore, the implications of this research extend beyond hepatocellular carcinoma. The success of CAR-macrophages in targeting NKG2D ligands may inspire similar approaches for other cancers that exploit comparable mechanisms of immune evasion. This versatility in application could herald a new era of CAR-modified cellular therapies that empower innate immune cells to take a more active role in cancer immunotherapy.

While the preclinical successes are encouraging, the study emphasizes the need for careful consideration as it moves toward clinical trials. Safety and efficacy remain paramount, and understanding the dosing parameters and potential off-target effects of these engineered macrophages will be critical in translating this research from bench to bedside. Collaborations with clinical centers will be integral in facilitating this transition and ensuring the therapeutic potential is realized in human populations.

This research positions CAR-macrophages not merely as a complementary therapy but as a potential cornerstone of novel treatment strategies for hepatocellular carcinoma. As insights into the immune landscape of tumors continue to deepen, such innovative methodologies will likely become integral components in the multifaceted approach to cancer treatment, reshaping the future of oncology.

In conclusion, the studies conducted by Zhao and colleagues present compelling evidence that harnessing NKG2D-specific CAR-macrophages can significantly enhance immune responses to hepatocellular carcinoma. With the promise of achieving long-term remission, this research lays the groundwork for future clinical applications, highlighting the necessity of continued exploration of the immune system’s potential in overcoming cancer’s challenges. As advancements in immunotherapy continue to revolutionize cancer treatment, approaches like this could ultimately lead to improved survival outcomes for patients facing this formidable disease.

Subject of Research: Hepatocellular carcinoma and its treatment with CAR-macrophages.

Article Title: Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma.

Article References:

Zhao, Z., Zheng, W., He, Y. et al. Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma.
Mol Cancer 25, 9 (2026). https://doi.org/10.1186/s12943-025-02538-w

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12943-025-02538-w

Keywords: CAR-macrophages, NKG2D, hepatocellular carcinoma, immunotherapy, cancer treatment.

Protein nanoparticles have long been recognized for their capacity to enhance immune responses by displaying multiple copies of antigens in periodic arrays that mimic the spatial arrangement of epitopes on actual pathogens. However, conventional nanoparticle platforms frequently rely on carriers derived from organisms unrelated to the target pathogen, which introduces risks of unwanted immune interference or suboptimal antigen presentation. Moreover, pre-existing immunity against the nanoparticle scaffold and concerns over potential autoimmunity prompted by conserved epitopes have restricted their widespread application.

Addressing this considerable challenge, the team engineered P. falciparum PLP synthase, a multisubunit enzyme complex with no known human ortholog, to serve as a self-derived nanoparticle scaffold. This innovation uniquely minimizes the risks of autoimmune reactions and pre-existing immunity. By fusing it genetically with two key Plasmodium antigens—the P. falciparum circumsporozoite protein (CSP), which plays a critical role during liver infection, and the Plasmodium vivax cell-traversal protein for ookinetes and sporozoites (CelTOS), essential for host cell penetration—the engineered nanoparticles induce robust, dual-specific antibody responses targeting different stages of the malaria parasite’s life cycle.

Detailed immunization studies showed that mice receiving three doses of this multivalent vaccine exhibited exceptionally high titers of antibodies against both CSP and CelTOS antigens. Most remarkably, these immunized mice experienced complete sterile protection when challenged with infectious Plasmodium sporozoites, a gold standard outcome in malaria vaccine development indicating elimination of the parasite before establishment of infection.

To reveal the structural basis underlying nanoparticle stability and antigen presentation, researchers utilized cutting-edge cryogenic electron microscopy (cryo-EM), resolving the PLP nanoparticle at an extraordinary resolution of 2.95 angstroms. This atomic-level structural insight allowed the identification and rational engineering of amino acid substitutions that enhanced the nanoparticle’s stability, ensuring consistent and scalable manufacturing feasibility without compromising antigen display or immunogenicity.

The vaccine platform’s intrinsic advantages stem not only from its parasite origin but also from its modular nature. Unlike carriers derived from bacterial or viral sources, the Plasmodium PLP synthase scaffold lacks sequence homology with human proteins, substantially reducing the risk of eliciting autoreactive immune responses. Furthermore, since the platform components are native to the same species as the targeted pathogen, this self-derivation facilitates more physiologically relevant antigen presentation, maximizing the quality of antibody binding and immune activation.

Additional evaluation of the particle’s biophysical properties confirmed favorable manufacturing parameters, such as thermal stability and structural integrity under formulation and storage conditions. This presents a compelling advantage over existing nanoparticle vaccines that often require complex stabilization strategies or cold chain logistics, thereby limiting their deployment in resource-limited endemic regions where malaria burden is highest.

From a translational perspective, this discovery opens a versatile avenue for multivalent infectious disease vaccine design. The principles demonstrated—deploying pathogen-derived enzymatic nanoparticles combined with structurally rational antigen engineering—could be adapted to other challenging pathogens requiring complex immunity, ranging from other parasitic diseases to emerging viruses.

The multivalent vaccine’s ability to target antigens from two distinct Plasmodium species further represents a significant leap beyond monovalent immunogens. Achieving cross-species protection could substantially curtail malaria transmission cycles, particularly in regions co-endemic for both P. falciparum and P. vivax, the two most widespread human malaria parasites.

In summary, this pioneering work disrupts conventional vaccine design paradigms by integrating molecular engineering, structural biology, and immunology innovations to create a malaria vaccine candidate with unprecedented levels of protection demonstrated preclinically. These findings propel Plasmodium PLP synthase nanoparticles to the forefront of next-generation vaccine platforms capable of eliciting sterile immunity, a long-sought goal in combating malaria’s global toll.

Looking towards clinical application, further studies in non-human primates and eventual human trials will be crucial to confirm safety, immunogenicity, and protective efficacy in diverse populations. The simplicity and potency of this malaria vaccine candidate raise hopes for addressing persistent vaccine challenges against parasitic infections and beyond.

This work exemplifies the power of leveraging pathogen biology itself to craft better vaccines, transforming inherent parasite molecules into powerful immunological tools. Such innovations offer promising strategies not only to end malaria but also to revolutionize vaccine development against a broad array of infectious diseases demanding next-level solutions.

As the global health community continues striving for durable malaria control and elimination, the introduction of PLP synthase-based nanoparticles heralds a new chapter where engineered biological systems from the pathogen can be turned against it to achieve sterile, vaccine-mediated immunity with far-reaching public health impact.

Subject of Research: Development of a Plasmodium falciparum-derived nanoparticle vaccine platform for multivalent malaria immunization.

Article Title: A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice.

Article References:
Shi, D., Ma, R., Gupta, R. et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02209-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41564-025-02209-y

The Coxsackie B1 virus has long posed a threat to public health due to its ability to cause severe infections, especially in young children and immunocompromised individuals. Traditional vaccine approaches have struggled with the virus’s genetic variability and immunoevasive strategies. This latest research, however, focuses on a more refined approach that exploits the principles of immunology and virology to enhance vaccine efficacy. By strategically modifying the viral capsid, researchers aimed to invoke a stronger and more targeted immune response without the interference of immunoreactive epitopes that could diminish the vaccine’s effectiveness.

In their studies, the team, led by Soppela and colleagues, employed advanced techniques in molecular biology and virology, which allowed them to generate virus-like particles (VLPs). These VLPs closely mimic the structure of the Coxsackie B1 virus but lack the viral genome, rendering them non-infectious. These particles serve as an ideal platform for vaccination, as they can elicit a strong immune response while remaining safe for administration. Such platforms have gained popularity in vaccine development due to their ability to present antigens to the immune system effectively.

The critical innovation in this vaccine lies in the exclusion of a highly conserved immunoreactive region from the capsid. This precise modification was aimed at reducing the potential for cross-reactivity with other serotypes or strains of enteroviruses while enhancing the production of neutralizing antibodies specific to the Coxsackie B1 virus. By excluding this particular region, the researchers have redirected the immune response, thus generating antibodies that are more effective against the virus while minimizing unwanted immune system interactions that can lead to adverse effects.

Animal models, particularly mice, were utilized to assess the efficacy of the modified vaccine. The results were promising, as the vaccine successfully induced a strong and specific neutralizing antibody response against the Coxsackie B1 virus, demonstrating its potential as a viable preventive strategy. The efficacy observed in murine trials suggests that the immune system recognizes the modified VLPs as foreign, leading to the production of antibodies and the activation of T-cells, which are critical for a protective immune response.

Furthermore, the study provides valuable insights into the kinetics of the immune response following vaccination. Researchers observed that the neutralizing antibodies reached peak levels within a specific timeframe post-vaccination, indicating effective immunogenicity. Additionally, the longevity of the immune response was evaluated, revealing that the protective antibodies persisted for an extended period. This long-lasting immunity is crucial, especially in light of the recurrent nature of Coxsackie virus infections.

Importantly, the vaccine’s safety profile was also extensively evaluated in the murine model. Researchers ensured that the excluded immunoreactive region did not compromise the safety of the vaccine, and no significant adverse effects were reported. This aspect is particularly important for public health strategies, as vaccine safety is paramount in building public trust and encouraging widespread vaccination.

The findings derived from this research could potentially lay the groundwork for human clinical trials, marking a significant step forward in the fight against Coxsackievirus and similar pathogens. If successful in human studies, this vaccine could represent a substantial advancement in the prevention of viral infections that can lead to severe health complications. The adaptability of using modified VLP vaccines also suggests that similar strategies could be employed for other viruses that exhibit similar genetic diversity and escape mechanisms.

As researchers continue to refine this vaccine technology, there is potential for applications beyond the Coxsackie B1 virus itself. The principles of excluding conserved immunoreactive regions may inspire new strategies in vaccine development for various viral diseases. Additionally, this research highlights the importance of understanding immune evasion strategies employed by viruses, providing insights that can help in crafting more effective vaccines.

In conclusion, the modified Coxsackie B1 virus-like particle vaccine presents a promising approach to combating enteroviral infections. The careful design of such vaccines, guided by a deep understanding of immunology and virology, could alter the landscape of how we approach vaccination against viruses that have historically posed significant challenges. As the scientific community advances in this domain, the potential for breakthroughs in public health remains vast and exciting.

The increasing complexity of viral pathogens necessitates a continual evolution of our strategies to combat them. The advancement of the Coxsackie B1 vaccine exemplifies the innovative spirit of modern immunology, paving the way for future success stories in viral vaccine development. As we look forward to the results from upcoming clinical trials, the hope for a safer, more effective vaccine against Coxsackie B1 virus becomes closer to reality.

Moreover, the collaboration between virologists, immunologists, and molecular biologists showcases the interdisciplinary efforts required to tackle the intricate challenges posed by viral diseases. This approach not only enhances the credibility of the findings but also fosters a robust scientific dialogue that can inspire future research endeavors.

In summary, the vaccine engineered to exclude a highly conserved immunoreactive region from the Coxsackie B1 virus capsid stands as a testament to the advancements in virology and immunization strategies. The path forward looks promising, with the potential to significantly impact public health in a new era of viral vaccine development.

Subject of Research: Coxsackie B1 virus-like particle vaccine development

Article Title: Coxsackie B1 virus-like particle vaccine modified to exclude a highly conserved immunoreactive region from the capsid induces potent neutralizing antibodies and protects against infection in mice.

Article References:

Soppela, S., González-Rodríguez, M., Stone, V.M. et al. Coxsackie B1 virus-like particle vaccine modified to exclude a highly conserved immunoreactive region from the capsid induces potent neutralizing antibodies and protects against infection in mice.
J Biomed Sci 32, 86 (2025). https://doi.org/10.1186/s12929-025-01183-1

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12929-025-01183-1

Keywords: Coxsackie B1 virus, vaccine, virus-like particles, immunology, neutralizing antibodies, enterovirus, immunoreactive regions, infection prevention.

Leishmaniasis, a disease that afflicts millions worldwide, is predominantly spread by the bite of infected sandflies. The resulting infection can lead to a spectrum of clinical manifestations ranging from cutaneous forms to more severe visceral leishmaniasis. Current treatment options, primarily based on antimonials and amphotericin B, are often fraught with limitations including toxicity, resistance, and high costs. Thus, the need for innovative and safer therapeutic strategies is more pressing than ever.

The researchers’ approach involved the utilization of recombinant DNA technology to produce a purified form of phospholipase A2 (PLA2) from scorpion venom. This enzyme is known for its role in disrupting cellular membranes, thus enhancing the immune response against invading pathogens. By engineering this potent enzyme, they aimed to unlock its therapeutic potential against leishmaniasis, which has long been a stubborn challenge for medical researchers.

The initial stages of the research comprised a comprehensive characterization of the recombinant PLA2. This process included determining its structural integrity and enzymatic activity, which are crucial for assessing its effectiveness. Using advanced techniques such as X-ray crystallography and mass spectrometry, the team meticulously analyzed the protein’s configuration, yielding insights that would later inform their experimental methodologies. The results indicated that the recombinant protein maintained its functional properties, setting the stage for subsequent in vitro and in vivo studies.

The in vitro studies were carried out using Leishmania protozoa in controlled laboratory settings. Results were exhilarating; the recombinant PLA2 displayed a remarkable inhibitory effect on the growth of Leishmania parasites. Notably, the team observed that treatment with the scorpion venom-derived protein led to a significant reduction in the viability of the parasites, showcasing an efficiency that far surpassed established therapies. These findings prompted further investigations into the mechanism of action, which revealed that the enzyme engages in direct cellular interactions, leading to increased cell lysis.

Following the encouraging laboratory results, the team transitioned to in vivo studies to evaluate the therapeutic efficacy of the recombinant PLA2 in animal models. These experiments were designed to replicate the complexities of the immune response seen in human leishmaniasis. Preliminary results indicated that treatment with the recombinant protein resulted in improved survival rates and reduced parasite load in infected animal subjects. Remarkably, the treated groups exhibited less severe symptoms compared to those receiving conventional therapies, underscoring the potential advantages of this novel treatment approach.

The implications of this research extend beyond merely improving treatment outcomes. The unique properties of phospholipase A2 suggest that it may also enhance the host’s immune response by promoting inflammation and activating immune cells. This dual mechanism could potentially mitigate the threat of parasite resistance, a growing concern in the field of tropical medicine. The researchers are optimistic that by harnessing the natural defenses offered by scorpion venom, they can contribute to a more robust and sustainable strategy against leishmaniasis.

As the study gains traction in the scientific community, it paves the way for future investigations into other venom-derived proteins. The diversity of bioactive compounds found in venom could lead to the discovery of additional therapeutic agents targeted at leishmaniasis and potentially other diseases caused by parasitic encounters. The versatility and efficacy of venom components could revolutionize our approach to treating various infectious diseases that have remained stubbornly resistant to existing therapies.

Ethical considerations surrounding the use of animal models in this research were rigorously addressed. The team adhered to globally recognized guidelines for the humane treatment of research subjects, ensuring that all protocols were thoroughly reviewed and approved by institutional committees. The researchers emphasize the importance of ethical practices in translational research, connecting their findings to real-world implications for patient care.

With these compelling results, the researchers are poised to transition into clinical trials, aiming to assess the safety and efficacy of the recombinant PLA2 in human subjects. Such trials would be monumental, establishing a pathway from laboratory success to clinical applicability. The anticipation surrounding these next steps underscores the excitement and optimism within the scientific community, particularly among those focused on infectious disease.

In conclusion, this pioneering research presents a significant leap forward in the battle against leishmaniasis. The potential of recombinant phospholipase A2 from scorpion venom as a therapeutic agent underscores the necessity for innovative approaches in combating infectious diseases. As researchers continue to unravel the mysteries of venom and its applications, the hope is that they will unearth new solutions capable of alleviating the burden of disease for millions around the globe.

This breakthrough not only heralds a new wave of pharmacological advancements but also rejuvenates the dialogue around the beneficial applications of biologically diverse resources found in nature. The team remains committed to their mission of translating these findings into actionable solutions in public health.

In light of these promising developments, the future of leishmaniasis treatment appears more hopeful than ever, with the potential for a revolutionary new weapon against one of the world’s most persistent infectious diseases.

Subject of Research: Anti-leishmanial activity of recombinant scorpion venom phospholipase A2.

Article Title: The recombinant protein of scorpion venom phospholipase A2 exhibits potential anti-leishmanial activity.

Article References:

Soltan-Alinejad, P., Ramezani, A., Asgari, Q. et al. The recombinant protein of scorpion venom phospholipase A2 exhibits potential anti-leishmanial activity.
Sci Rep (2025). https://doi.org/10.1038/s41598-025-29796-4

Image Credits: AI Generated

DOI: 10.1038/s41598-025-29796-4

Keywords: Leishmaniasis, scorpion venom, phospholipase A2, recombinant protein, anti-leishmanial activity.

The concept of prehabilitation, often likened to athletic training for a marathon, aims to optimize a patient’s condition to withstand the physiological stress of surgery. Unlike routine advice given in many healthcare settings, the Stanford study uniquely integrates personalized coaching with specialized interventions encompassing nutrition, physical activity, cognitive training, and mindfulness. This multi-dimensional approach addresses the complex interplay of physical and mental readiness essential for coping with surgical trauma, an ordeal whose impact can rival extreme physical exertion.

This randomized controlled trial enrolled adult participants scheduled for major surgeries—predominantly abdominal operations related to cancer or gastrointestinal diseases—approximately four to five weeks before their procedures. The study compared a standard prehabilitation protocol, which relied on informational booklets providing general guidelines for exercise, Mediterranean-style nutrition, cognitive exercises via apps, and mindfulness techniques, with an intensified personalized program involving twice-weekly remote coaching sessions. The latter paired patients with a physical therapist for exercise regimen customization and a physician who addressed nutrition, cognition, and behavioral health, tailoring interventions based on real-time assessments including patients’ kitchen inventory.

Critically, the outcomes of this study highlight not only improved clinical results but also fundamental immunological modulations. Inflammatory markers and immune cell reactivity were rigorously evaluated through sophisticated blood assays simulating surgical stress conditions. Patients undergoing personalized prehab exhibited a substantially more balanced immune profile, characterized by attenuated innate immune over-reactivity and lower baseline inflammation. Such modulation may underpin the significant reduction in post-operative complications observed—only four out of twenty-seven in the personalized group experienced moderate-to-severe complications versus eleven out of twenty-seven in the standard group.

The personalized prehab cohort demonstrated marked improvements across a spectrum of physical and cognitive metrics, including endurance, strength, and executive function tasks, in stark contrast to the limited gains seen in the standard protocol group. This cognitive and physiological enhancement is posited to prime the body’s immune and nervous systems for surgical trauma, promoting more effective tissue repair, infection resistance, and neurocognitive function. Notably, the normalization of adaptive immunity in specific T cell subsets associated with post-surgical cognitive decline suggests prehabilitation’s role extends beyond physical resilience into preserving brain health.

One of the most noteworthy aspects of this research is the patient experience and adherence. The personalized approach, embracing remote yet interactive coaching, fostered a stronger therapeutic alliance, allowing patients to receive feedback and adjust their routines actively. This high-touch model addresses the common challenge of compliance in behavioral interventions, particularly in high-stress phases when patients may feel overwhelmed and isolated. The convenience of remote interactions combined with individualized guidance emerged as a pivotal factor in successful behavior modification.

The mechanistic revelations about prehabilitation’s immune effects represent a paradigm shift in perioperative medicine. Historically, prehab programs focused on physical conditioning without a comprehensive understanding of their biological impact. By elucidating how personalized interventions can recalibrate immune responses, the Stanford study provides a scientific foundation for integrating prehabilitation into standard surgical care. This immunomodulation resembles the benefits typically attributed to pharmacological treatments, yet it harnesses non-pharmaceutical, patient-empowered strategies free from adverse effects.

Looking forward, the challenge lies in scaling personalized prehabilitation to broader patient populations and diverse healthcare settings. Such expansion will require careful patient selection, resource allocation, and possibly digital health platforms to deliver coaching at scale without compromising personalization. Meanwhile, for patients unable to access formal programs, incremental lifestyle improvements—especially in physical activity—remain strongly encouraged as they offer a foundation for enhancing surgical resilience.

In sum, this pioneering research from Stanford Medicine redefines the preoperative period as an opportunity not only for physical preparation but for systemic immune and cognitive strengthening. By embracing personalized prehabilitation, the medical community can transform the narrative of surgery from one of passive endurance to active patient empowerment, potentially revolutionizing recovery trajectories and long-term health outcomes.

Subject of Research: People
Article Title: Immune Modulation by Personalized vs Standard Prehabilitation Before Major Surgery
News Publication Date: 12-Nov-2025
Web References: https://med.stanford.edu/
References: Published in JAMA Surgery
Keywords: Surgery, Prehabilitation, Immune Modulation, Personalized Medicine, Perioperative Care

In a groundbreaking study recently published, a novel modular strategy has emerged, using a single-component nanobody binder to attach a variety of antigens noncovalently to functional particles derived from a licensed hepatitis E vaccine. This technique represents a significant leap forward, allowing for the development of customizable combination vaccines that could be rapidly advanced into the clinical setting. Central to this innovation was the immunization of an alpaca with the hepatitis E vaccine, which produced a range of nanobodies—small, robust antibody fragments that can bind to specific targets with high affinity.

The researchers employed phage display to screen the nanobodies, aiming to identify one that could selectively bind to specific sites on the particle surface of the hepatitis E vaccine without interfering with its native immunogenicity. Among the various nanobodies tested, one candidate stood out: designated P1-5B, this particular nanobody exhibited a unique ability to bind to recessed, non-immunodominant regions on the viral particles. This characteristic is pivotal, as it allows for the stable display of antigens while preserving the particle’s inherent properties, which are important for inducing an effective immune response.

Utilizing the P1-5B nanobody binder, the research team produced three distinct vaccine formulations. These formulations displayed a remarkable range of antigens, tallying between five to eleven different components. The antigens included a variety of variants from notable pathogens, such as the SARS-CoV-2 coronavirus responsible for COVID-19, the influenza virus, and the respiratory syncytial virus (RSV). The capacity to incorporate multiple antigens into a single formulation could drastically change the landscape of vaccination strategies, especially in addressing multifactorial epidemic outbreaks.

Furthermore, these multivalent particles demonstrated high-affinity assembly, an important aspect that can contribute to the stability and effectiveness of the vaccine. Notably, the formulations maintained solubility, addressing another significant challenge in vaccine preparation. The data collected during the study indicated that the neutralizing titres generated by the vaccines were up to three log units higher compared to those produced by traditional soluble antigen formulations. This substantial increase in immune response suggests that the novel approach not only enhances antigen presentation but also amplifies the overall efficacy of the vaccine.

Animal studies conducted using the candidate vaccines have yielded promising results across multiple species, including mice, hamsters, and non-human primates. The findings revealed that these advanced vaccine formulations conferred robust protection against the targeted viral infections, demonstrating the versatility and power of the modular strategy employed. Additionally, the safety profile of the candidate vaccines was favorable, which is a critical factor when assessing any new immunotherapy. Adverse effects can drastically impact public acceptance and trust, thus highlighting the importance of thorough safety evaluations during the development phase.

The implications of this research could transcend conventional vaccination strategies, ushering in a new era where combination vaccines are not only feasible but also practical for widespread vaccination campaigns. The ability to adapt this plug-and-display system to accommodate various pathogens has the potential to revolutionize how global health authorities approach immunization in the face of emerging and re-emerging infectious diseases. By addressing technical complexities associated with vaccine formulation through innovative strategies, researchers can pave the way for more effective response measures during pandemics and epidemics.

Moreover, this modular approach may also foster faster vaccine development timelines. This agility is essential in situations where swift responses are paramount, such as during viral outbreaks. By leveraging existing licensed vaccine platforms, researchers can rapidly tailor formulations to address pressing health concerns without starting from scratch each time. This adaptability could ultimately save lives by ensuring that protective strategies are in place before outbreaks escalate.

As the scientific community celebrates these advancements, the ongoing study of nanobody technology and its application in immunology continues to unfold. The findings presented in this research illustrate not only the potential for nanobodies to enhance vaccine design but also their role in building a robust defense against complex infections that challenge public health globally. As more is understood about the intricacies of immune responses and the specific roles of various antigens, we may see further refinements in combination vaccine strategies.

Future research endeavors will undoubtedly seek to expand on these findings, exploring other combinations of antigens and their effects on immune responses. There is also immense potential for the application of this strategy across other vaccine platforms, thereby broadening the scope of protection available against not only respiratory viruses but also a myriad of other infectious diseases. The scientific community remains poised to embrace innovations that push the boundaries of what vaccines can achieve, culminating in a healthier world.

In summary, the development of a nanobody-based combination vaccine system leveraging licensed protein nanoparticles represents a pivotal advancement in the ongoing battle against infectious diseases. By simplifying immunization processes and enhancing protective efficacy while maintaining a favorable safety profile, this innovative approach could indeed reshape the future of vaccine technology.

Subject of Research: Combination vaccines using nanobody technology

Article Title: Nanobody-based combination vaccine using licensed protein nanoparticles protects animals against respiratory and viral infections.

Article References:

Li, T., Xue, W., Zhang, S. et al. Nanobody-based combination vaccine using licensed protein nanoparticles protects animals against respiratory and viral infections.
Nat. Biomed. Eng (2025). https://doi.org/10.1038/s41551-025-01529-y

Image Credits: AI Generated

DOI:

Keywords: combination vaccines, nanobodies, immunogenicity, respiratory infections, SARS-CoV-2, influenza virus, respiratory syncytial virus, vaccine technology.

PD-L1, an immune checkpoint protein, is known for its role in cancer cells to evade the immune response. By binding to PD-1 on T cells, it effectively inhibits T cell proliferation and cytokine production, creating a dampened immune response. On the other hand, IL-8 is a chemokine associated with tumor progression, which attracts immune cells to the tumor site but paradoxically contributes to an immune suppressive microenvironment. The ability of BP2402 to simultaneously engage both pathways signifies a paradigm shift in therapeutic strategies for TNBC, where conventional monotherapies have often fallen short.

The preclinical studies conducted by the team demonstrated that BP2402 could markedly enhance the infiltration of cytotoxic T cells into the tumor microenvironment. This infiltration is crucial, as on-site T cells can mount a more potent and localized attack against tumor cells. The enhanced antitumor immune response observed results from the bispecific antibody’s ability to block the PD-1/PD-L1 interactions while simultaneously modulating IL-8 signaling, which orchestrates the tumor’s immune infiltrate. These results present an empowering narrative that bi-specific antibodies like BP2402 could galvanize a more robust immune response, steering the body’s defenses toward a more aggressive stance against cancer.

Additionally, researchers noted that the dual inhibition not only improved T cell activity but also reduced the overall levels of IL-8 in the tumor microenvironment. By lowering the levels of this chemokine, BP2402 holds the potential to eliminate the detrimental effects associated with IL-8’s immunosuppressive role. This could lead to an environment where T cells can function more effectively, unencumbered by the cellular signals that typically lead to their exhaustion. The balance between promoting T cell activities and mitigating immunosuppressive signals is critical in cancer therapy, and BP2402 appears to perform this delicate dance with exceptional finesse.

The encouraging findings from the TNBC mouse model indicate that BP2402 not only induces a noteworthy tumor regression but also significantly alters the inflammatory signaling pathways at play. In tumors treated with BP2402, a marked shift towards a pro-inflammatory environment was observed. This change was evidenced by increased production of various cytokines that foster robust immune responses. Such alterations in the inflammatory landscape could indicate a reprogramming of the tumor’s signaling networks, redirecting them towards an anti-tumorigenic profile.

The implications of these findings are vast. Given that TNBC is particularly known for its aggressiveness and lack of targeted therapy options, the advent of a bispecific antibody like BP2402 could herald a new chapter in the treatment of this subtype. It not only provides a dual mechanism of action against tumor escape strategies but also opens up avenues for potential combination therapies with existing standard-of-care agents, ultimately leading to improved outcomes for patients grappling with this disease.

Expanding the breadth of this research, the authors also highlighted that the safety profile of BP2402 was favorable, with no significant adverse effects reported in the treated mice. This data is vital when considering the translation of these findings into clinical settings. A novel therapy’s launch into human clinical trials hinges not just on its efficacy but also on its tolerability. The favorable safety profile of BP2402 sets the stage for future human studies, indicating that it could be a viable addition to the therapeutic arsenal in the fight against TNBC.

As ongoing research continues to validate these preclinical results, scientists are urged to explore the mechanistic pathways further. Understanding how BP2402 modifies the tumor microenvironment at a molecular level could provide crucial insights into further enhancing its efficacy. Potential resistance mechanisms to bispecific antibodies deserve particular attention, ensuring that the therapeutic potency of BP2402 can be maximized in patient populations that may exhibit resistance to monotherapies.

Moreover, the advent of this research aligns with the broader trend of personalized medicine in oncology, whereby treatment is increasingly tailored to the specific characteristics of both the tumor and the patient. The integration of biomarkers that can predict responses to BP2402 could enhance treatment precision, ensuring that patients most likely to benefit from such bispecific therapies are identified beforehand, ultimately optimizing therapeutic choices.

In conclusion, the study conducted by Song et al. surrounding the innovative bispecific antibody BP2402 illustrates a promising frontier in the fight against triple-negative breast cancer. By targeting both PD-L1 and IL-8, the research team is unveiling a potential that fundamentally alters therapeutic interventions and immune engagement strategies. The implications of this breakthrough are vast, offering hope to patients and paving the way for more effective treatment measures that could transform outcomes in the realm of oncology. As the medical community eagerly anticipates the transition of BP2402 from the laboratory bench to the clinical setting, the future may indeed be brighter for those affected by TNBC, as this novel therapeutic option emerges with the potential to shift the current paradigm in cancer treatment.

Subject of Research: Bispecific antibody targeting PD-L1 and IL-8 in triple-negative breast cancer.

Article Title: A novel anti-PD-L1/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model.

Article References:

Song, L., Tang, S., Pi, X. et al. A novel anti-PD-L1/IL-8 bispecific antibody BP2402 enhances antitumor immunity and modulates inflammatory signaling in triple-negative breast cancer mice model.
J Transl Med 23, 1056 (2025). https://doi.org/10.1186/s12967-025-07105-x

Image Credits: AI Generated

DOI:

Keywords: Bispecific antibody, PD-L1, IL-8, triple-negative breast cancer, immunotherapy, tumor microenvironment, T cells, cytokines, safety profile, personalized medicine.